vitamin C - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 2.79 [0.28, 28.01]< 10%2 studies (2/-)19.3 %some concernnot evaluable moderatecrucial-
clinical improvement 1.41 [0.41, 4.91]> 138%2 studies (2/-)70.7 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 3.14 [0.60, 16.38]> 10%1 study (1/-)91.2 %some concernnot evaluable moderateimportant-
hospitalization 1.40 [0.46, 4.29]< 10%2 studies (2/-)27.6 %some concernnot evaluable moderateimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.